10 results about "Epitope specificity" patented technology

An epitope-specific antigen-binding molecule specific for the human metapneumovirus (hMPV) fusion (F) protein is provided, which comprises a variable domain that contacts the hMPV F protein. The hMPV F protein-specific antigen-binding molecule comprises a heavy chain and a light chain. Also provided is a method for detecting an antibody specific for the hMPV F protein, comprising: a.) contacting a biological sample with the hMPV F protein; and b.) contacting the epitope-specific antigen-binding molecule with the hMPV F protein.

The present invention relates to the field of immunotherapy, in particular to diseases associated with Epstein-Barr virus (EBV, also known as human gamma herpesvirus 4), such as cancer or post-transplant lymphoproliferative disease, in particular to adoptive T cell therapy or T cell receptor (TCR) gene therapy. The present invention provides a combination of nucleic acids encoding at least two TCR constructs or corresponding proteins or host cells, wherein each TCR construct is capable of specifically binding to its respective epitope in the context of a respective MHC I, and wherein the epitopes are derived from different antigens expressed by the same infectious agent or cancer, such as EBV antigens. The present invention further provides specific nucleic acids encoding a TCR alpha chain construct (TRA) and / or a TCR beta chain construct (TRB) of a TCR construct specific for an epitope complexed with human MHC I, wherein the epitope is an epitope of an Epstein-Barr virus protein, the TCR construct being specific for an epitope from LMP2A, LMP1 or EBNA3C. Proteins encoded by said nucleic acids, corresponding host cells, as well as pharmaceutical compositions and kits are also an object of the present invention.

The invention discloses a salmonella H: i epitope specific monoclonal antibody and application thereof, the salmonella H: i epitope specific monoclonal antibody is secreted by hybridoma cells with the preservation number of CCTCC NO: C202645, and the antibody has the advantages of high titer and strong specificity. According to the blocking ELISA detection kit constructed by the antibody and the detection method of the blocking ELISA detection kit, the antibody containing H: i antigen epitope salmonella in infected animal serum can be specifically detected, the antibody does not react with antibodies containing no H: i antigen epitope salmonella and non-salmonella, the sensitivity, specificity and stability are good, and the detection method is simple and convenient. And a new method is provided for direct serological detection of H: i antigen epitope-containing salmonella infection of mouse typhimurium, kafenkii and the like.

An immunoresponsive cell, such as a T-cell expressing(i) a second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; and(ii) a chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

Provided herein are methods for making, and epitope-targeted, conditionally-activated, pro-drug, antibody, comprising: complementarity determining regions (CDRs) from an antibody identified from an in vivo, in vitro, or in silico antibody library; one or more engineered epitope masks connected to a linker, wherein the linker comprises a peptide, a polymer, or a chemical-linker that is cleaveable in vivo at a target site by an enzyme or cleaved chemically, and wherein the one or more engineered epitope masks binds the epitope-specific antibody at the CDRs of the epitope-specific antibody; and wherein the one or more engineered epitope masks linked to the antibody via the linker, wherein the masks are conditionally bound to the CDRs of the epitope-specific antibody, and wherein cleavage of the linker releases the one or more engineered epitope masks from the antigen binding site.

A light-initiated chemiluminescence assay kit for phosphorylated Tau protein p-tau 217, a use method thereof and the use thereof. The kit comprises an R1 reagent, an R2 reagent and an R3 reagent. The R1 reagent comprises luminescent microspheres and first antibodies each of which coats a luminescent microsphere, has a first tag molecule and can specifically bind to p-tau 217. The R2 reagent comprises second antibodies carrying second tag molecules. The R3 reagent comprises first pairing molecules that can specifically bind to the first tag molecules. The first antibodies and the second antibodies can specifically bind to different epitopes of p-tau 217, and one first pairing molecule can bind to at least two first tag molecules.

Described herein is an active Alzheimer's Disease (AD) immunotherapy based on a nanoparticle vaccine comprising a plurality of Aβ peptides and / or a plurality of tau peptides. These peptides may correspond to both soluble and aggregated targets and are displayed on the surface of immunogenic liposomes in an orientation that maintains reactivity with epitope-specific monoclonal antibodies. Also provided are methods of making and using same.

Provided are epitope-specific antigen-binding molecules specific to a human metapneumovirus (hMPV) Fusion (F) protein, in which the antigen-binding molecule comprises a variable domain that contacts the hMPV F protein. The antigen-binding molecule specific to an hMPV F protein comprises a heavy chain and a light chain. Further provided are methods for detecting antibodies specific to an hMPV F protein, a method comprising: a.) contacting a biological sample with an hMPV F protein; and b.) contacting an epitope-specific antigen-binding molecule with the hMPV F protein.

An immunoresponsive cell, such as a T-cell expressinga second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; anda chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

Provided herein are methods for making epitope-targeted, conditionally activated pro-antibodies comprising: complementarity determining regions (CDRs) from an antibody identified from an in vivo, in vitro, or in silico antibody library; and one or more engineered epitope masks linked to a linker, wherein the linker comprises a peptide, polymer, or chemical linker that can be cleaved in vivo at a target site by an enzyme or chemically, and wherein the one or more engineered epitope masks bind to an epitope-specific antibody at a CDR of the epitope-specific antibody; and the one or more engineered epitope masks are linked to the antibody via the linker, wherein the mask is conditionally bound to the CDR of the epitope-specific antibody, and wherein cleavage of the linker releases the one or more engineered epitope masks from the antigen binding site.